Vancouver-based Tekmira Pharmaceuticals, a developer of RNA interference (RNAi) therapeutics, has entered a new research collaboration with Pfizer. The companies will collaborate on evaluating Tekmira’s stable nucleic acid-lipid particle (SNALP) technology to deliver small interfering RNA (siRNA) molecules provided by Pfizer. Tekmira will be responsible for preparing the SNALP formulations and Pfizer will evaluate the formulations in preclinical models.
Read more : Tekmira and Pfizer initiate new research collaboration